The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDNL.L Regulatory News (DNL)

  • There is currently no data for DNL

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Results of Annual General Meeting

23 Nov 2016 11:30

RNS Number : 9559P
Diurnal Group PLC
23 November 2016
 

23 November 2016

 

 

Diurnal Group plc

("Diurnal" or the "Company")

 

Results of Annual General Meeting

 

 

Diurnal Group plc (AIM: DNL), the specialty pharmaceutical company targeting patient needs in chronic endocrine (hormonal) diseases, announces that all resolutions proposed to shareholders at its Annual General Meeting held today were duly passed. All resolutions were approved on a show of hands. The number of proxy votes received for each resolution is set out below.

 

 

Resolution

For (including discretionary votes)*

Against*

Withheld

Ordinary Resolutions (requires 50% majority)

1. To receive and adopt the Company's audited annual report and accounts for the year ended 30 June 2016.

39,347,209

100%

0

0%

0

2. To reappoint Peter Allen as a director.

39,347,209

100%

0

0%

0

3. To reappoint Ian Ardill as a director.

39,347,209

100%

0

0%

0

4. To reappoint John Goddard as a director.

39,347,209

100%

0

0%

0

5. To reappoint Alan Raymond as a director.

39,347,209

100%

0

0%

0

6. To reappoint Richard Ross as a director.

39,347,209

100%

0

0%

0

7. To reappoint Martin Whitaker as a director.

39,347,209

100%

0

0%

0

8. To reappoint Sam Williams as a director.

39,347,209

100%

0

0%

0

9. To receive and approve the directors' remuneration report contained within the annual report and accounts for the year ended 30 June 2016.

39,347,209

100%

0

0%

0

10. To reappoint KPMG LLP as auditors of the Company.

39,347,209

100%

0

0%

0

11. To authorise the directors to determine the remuneration of the auditors.

39,347,209

100%

0

0%

0

12. To authorise the directors to allot shares.

39,347,209

100%

0

0%

0

Special Resolutions (requires 75% majority)

13. To authorise the directors to disapply pre-emption rights.

39,347,209

100%

0

0%

0

14. To authorise the Company to make market purchases.

39,347,209

100%

0

0%

0

 

 

* A vote withheld is not a vote in law and is not counted in the calculation of the votes for or against a resolution; the percentage of votes cast therefore excludes withheld votes.

 

On 23 November 2016 there were 52,210,759 Diurnal Group plc ordinary shares in issue. Shareholders are entitled to one vote per share held.

 

The full text of each resolution passed at the Annual General Meeting held earlier today, is set out in the Notice of Annual General Meeting, included in the 2016 Annual Report, which is available on the Company's website www.diurnal.co.uk.

 

 

Please further information, please visit www.diurnal.co.uk or contact:

 

Diurnal Group plc

+44 (0)20 3727 1000

Martin Whitaker, CEO

Ian Ardill, CFO

Numis Securities Ltd

+44 (0)20 7260 1000

Nominated Adviser: Michael Meade, Freddie Barnfield, Paul Gillam

Corporate Broking: James Black

FTI Consulting

+ 44 (0)20 3727 1000

Simon Conway

Victoria Foster Mitchell

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
RAGBJBBTMBBTBPF
Date   Source Headline
12th May 20213:44 pmRNSDirector Dealings
12th May 20211:58 pmRNSHolding(s) in Company
12th May 202112:08 pmRNSHolding(s) in Company
12th May 20217:00 amRNSAgreement with Citrine Medicine for Efmody
11th May 20214:43 pmRNSHolding(s) in Company
11th May 20213:25 pmRNSHolding(s) in Company
10th May 202110:26 amRNSResult of General Meeting
23rd Apr 20217:00 amRNSGrant of second European Patent for Alkindi
21st Apr 202111:51 amRNSResult of Placing and Subscription
21st Apr 20217:00 amRNSProposed Placing, Subscription and Open Offer
15th Apr 20219:49 amRNSRequest for Efmody Orphan Designation withdrawn
26th Mar 20212:06 pmRNSSecond Price Monitoring Extn
26th Mar 20212:00 pmRNSPrice Monitoring Extension
26th Mar 202111:57 amRNSEMA issues positive opinion for second product
15th Mar 20217:00 amEQSEdison Investment Research Limited: Diurnal Group (DNL): Initiation - Improving treatments for endocrine disorders
10th Mar 20219:44 amRNSHolding(s) in Company
8th Mar 20215:34 pmRNSHolding(s) in Company
25th Feb 20217:15 amEQSHardman & Co Research: Diurnal Group (DNL): Attention turning to Chronocort(R)
24th Feb 20217:00 amRNSShares and AJ Bell Investor Evening Webinar
23rd Feb 20217:01 amRNSInterim Results
23rd Feb 20217:00 amRNSChronocort agreement with Consilient for Nordics
2nd Feb 20217:01 amRNSChronocort results published in JCEM
27th Jan 20219:00 amRNSPrice Monitoring Extension
27th Jan 20217:00 amRNSChina licencing agreement with Citrine for Alkindi
14th Jan 20217:01 amRNSBusiness and trading update
14th Jan 20217:00 amRNSAgreement with Eton for Alkindi extended to Canada
13th Jan 202110:07 amRNSAgreement with Er-Kim for distribution in Turkey
12th Jan 20217:00 amRNSChronocort MAA Submitted to the UK MHRA
11th Jan 20217:00 amRNSGrant of European Patent for Chronocort
22nd Dec 20203:29 pmRNSIssue of LTIP Awards
11th Dec 20202:02 pmRNSExercise of Options, Issue of Equity and TVR
23rd Nov 20207:00 amRNSExercise of Options, Issue of Equity and TVR
20th Nov 202012:06 pmRNSResult of Annual General Meeting
20th Nov 20207:00 amRNSGrant of European Patent for Alkindi
10th Nov 20207:00 amRNSNotice of Interim Results
2nd Nov 20204:47 pmRNSHolding(s) in Company
30th Oct 202011:34 amRNSHolding(s) in Company
30th Oct 20208:37 amRNSHolding(s) in Company
29th Oct 202010:30 amRNSHolding(s) in Company
29th Oct 20209:25 amRNSDirector Dealings
28th Oct 202012:49 pmRNSResult of General Meeting and Open Offer
21st Oct 20207:00 amRNSMAA for Alkindi submitted to Swissmedic
19th Oct 20207:00 amRNSVesting of LTIP awards
9th Oct 202010:37 amRNSResult of Placing, Open Offer and Notice of GM
9th Oct 20207:00 amRNSProposed Placing and Open Offer
8th Oct 20202:28 pmRNSPosting of Annual Report and AGM Notice
30th Sep 20204:41 pmRNSSecond Price Monitoring Extn
30th Sep 20204:35 pmRNSPrice Monitoring Extension
30th Sep 20208:15 amEQSHardman & Co Research: Diurnal (DNL): And then there were three
30th Sep 20207:00 amRNSAlkindi Sprinkle approved by US FDA

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.